Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Voltage-gated potassium channel, KCNQ (Kv7-like) alpha-subunit. C. elegans kqt-1 ortholog | 0.018 | 0.1605 | 0.3948 |
Schistosoma mansoni | hyperpolarization activated cyclic nucleotide-gated potassium channel | 0.0098 | 0.0181 | 0.043 |
Loa Loa (eye worm) | hypothetical protein | 0.0149 | 0.1061 | 0.244 |
Echinococcus multilocularis | voltage gated potassium channel | 0.0122 | 0.0594 | 0.0421 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0149 | 0.1061 | 0.2525 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0242 | 0.2681 | 1 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0306 | 0.379 | 0.3675 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0329 | 0.4203 | 1 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0122 | 0.0594 | 0.1414 |
Echinococcus granulosus | potassium voltage gated channel protein | 0.0149 | 0.1061 | 0.0897 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0122 | 0.0594 | 0.0421 |
Schistosoma mansoni | hyperpolarization activated cyclic nucleotide-gated potassium channel | 0.0098 | 0.0181 | 0.043 |
Echinococcus multilocularis | potassium voltage gated channel subfamily KQT | 0.018 | 0.1605 | 0.1451 |
Echinococcus granulosus | potassium voltage gated channel subfamily A | 0.0149 | 0.1061 | 0.0897 |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.0306 | 0.379 | 1 |
Schistosoma mansoni | cyclic-nucleotide-gated cation channel | 0.0098 | 0.0181 | 0.043 |
Schistosoma mansoni | cyclic-nucleotide-gated cation channel | 0.0098 | 0.0181 | 0.043 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0122 | 0.0594 | 0.0421 |
Brugia malayi | Voltage-gated potassium channel, Shaker-family (KCNA, Kv1-like) alpha-subunit | 0.0149 | 0.1061 | 0.244 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0242 | 0.2681 | 1 |
Loa Loa (eye worm) | voltage-gated potassium channel | 0.0116 | 0.0497 | 0.0876 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0098 | 0.0181 | 0.043 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0149 | 0.1061 | 0.2525 |
Loa Loa (eye worm) | hypothetical protein | 0.0271 | 0.3196 | 0.8354 |
Echinococcus multilocularis | potassium voltage gated channel subfamily A | 0.0145 | 0.0994 | 0.0829 |
Echinococcus granulosus | voltage gated potassium channel | 0.0122 | 0.0594 | 0.0421 |
Schistosoma mansoni | voltage-gated potassium channel KCNQ | 0.018 | 0.1605 | 0.382 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0122 | 0.0594 | 0.1414 |
Brugia malayi | Voltage-gated potassium channel, EAG (KCNH1)-related. C. elegans egl-2 ortholog | 0.0122 | 0.0594 | 0.1145 |
Loa Loa (eye worm) | hypothetical protein | 0.0122 | 0.0594 | 0.1145 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0306 | 0.379 | 0.3675 |
Brugia malayi | Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog | 0.0306 | 0.379 | 1 |
Echinococcus granulosus | potassium channel KvQLT family member kqt 1 | 0.018 | 0.1605 | 0.1451 |
Schistosoma mansoni | cyclic-nucleotide-gated cation channel | 0.0098 | 0.0181 | 0.043 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0329 | 0.4203 | 1 |
Echinococcus multilocularis | potassium voltage gated channel protein | 0.0149 | 0.1061 | 0.0897 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 21.1923 uM | PubChem BioAssay. qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 26.8545 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (binding) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase. (Class of assay: confirmatory) [Related pubchem assays: 1379 ] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.